Bôle-Richard, E <br/><br/>
Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.  [electronic resource] 

 -  Gene therapy  08 2016 
 - 664-72 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5462 
<br/><br/><label>Standard No.: </label>10.1038/gt.2016.39  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD19--genetics<br/>Azacitidine--pharmacology<br/>Bone Marrow Transplantation--adverse effects<br/>Caspase 9--genetics<br/>DNA Methylation--drug effects<br/>Genes, Transgenic, Suicide--genetics<br/>Genetic Therapy--methods<br/>Graft vs Host Disease--etiology<br/>Humans<br/>Jurkat Cells<br/>Organic Chemicals--pharmacology<br/>Transplantation, Homologous--methods